Menopause Treatment Market Report Scope & Overview:
The menopause treatment market size was valued at USD 17.84 billion in 2024 and is expected to reach USD 27.23 billion by 2032, growing at a CAGR of 5.44% over 2025-2032.
Increasing awareness about women's health, improving diagnosis rates for menopause, coupled with growing demand for both hormonal and non-hormonal therapies, are major dynamics fuelling the growth of the market. By 2030, more than 1.2 billion women globally are projected to have reached menopausal or postmenopausal age, furthering the need for symptom relief treatments that work.
In March 2024, Theramex joined forces with ObsEva to market nolasiban, a novel oral treatment for fertility and other hormone-related disorders in development, as an example of the R&D pipeline broadening its scope.
Despite being a first-line treatment for menopausal symptoms, Hormone Replacement Therapy (HRT) is falling out of favour; the era is over with recent novel alternatives, such as Neurokinin-3 (NK3) receptor antagonists and non-hormonal repositioning of SRRIs moving into clinical studies. Research and development investments are on the rise as well; for instance, Astellas received FDA approval in 2023 for its non-hormonal therapy for moderate-to-severe vasomotor symptoms (veporzana). Additionally, the FDA and EMA are facilitating pathways for menopause treatments through regulation, thus promoting innovation. In addition, the uptake of digital health platforms and personalized care models is increasing, which enhances patient access and compliance. This is likely to influence the demand for natural, personalized solutions, result in increased healthcare spending, and positively impact growth opportunities in countries including the U.S. and Germany with supportive reimbursement policies.
In May 2023, the approval of Veozah (fezolinetant) at Astellas blazed a trail for non-hormonal menopause therapies.
Market Dynamics:
Drivers:
-
Growing Healthcare Awareness Among Aging Female Populations, Advancements in Therapy Options, and Increased R&D Investments Fuel Market Growth
More than 75% of women suffer from moderate-to-severe menopausal symptoms, leading to a significant need for hormonal and non-hormonal therapies. Hormone therapy is widely available as well; Amneal Pharmaceuticals and Organon have further broadened their portfolios, while biotech players are making headway into the more nascent non-hormonal categories. Then in 2024, the NIH awarded more than USD 45 million to advance scientific discovery around women's midlife health and included in its directives that a subsequent call must focus on improving care for afflicted women. Moreover, the presence of OTC supplements and consumer-driven health trends has furthered supportive demand through online and retail pharmacies. Theoretically speaking, even regulators have signalled their intent to support development. EMA’s updated guidelines in 2023 focused on quality & safety for new menopause therapies, favourably enhancing the likelihood of market entry. The market has also been driven by rising use of digital health platforms such as Caria and Balance, for symptom monitoring and personalized care, which have better served treatment access and patient engagement.
Restraints:
-
Menopause Treatment Space Faces Considerable Barriers Including Safety Concerns, Underdiagnosis, and Limited Healthcare Access in Low-Income Settings
HRT (hormone replacement therapy) works but is associated with risks including breast cancer and cardiovascular disease, so understandably, patients are willing to previously after effective management. A 2023 study of menopausal women, published in The Lancet, found that only about 20% of women with menopausal symptoms receive any clinical treatment due to either low awareness or bias from the provider. Moreover, varying global reimbursement policies limit patient access primarily in regions where the concept of menopause as a medical condition is unknown. There are also disruptions to the supply side, such as production and raw material sourcing problems that bioidentical hormones and herbal products must face. Regulatory scrutiny is intense, such as the boxed warnings on estrogen-containing products mandated by the FDA, which has effectively discouraged a broader application. The clinical trials for the treatment of menopause face specific recruitment problems due to taboos and lower participation, leading to slow innovation and an approval process.
Segmentation Analysis:
By Treatment Type
In 2024, hormonal therapies dominated the market with an estimated share of 58.2%, due to high adoption of estrogen and combination treatments for vasomotor and genitourinary symptoms. The high clinical efficacy and physician familiarity with HRT secured its market dominance.
The segment of non-hormonal therapies is exhibiting the highest growth since people have started realizing the advantages that non-hormonal therapies offer over hormonal therapy. Novel selective NK3 receptor antagonists and SSRIs are increasingly becoming the standard of care, notably in women with contraindications to hormones.
By Route of Administration
In 2024, oral administration dominated the market with a share of 41.7% due to patient comfort and long-established penetration, and with the wide availability of tablets and capsules segment. Topical/Transdermal continues to grow at the fastest rate, partially due to the lower risk of systemic side effects and constant hormone exposure; estrogen patches and gels drive growth.
By Formulation Type
In 2024, the market accounted for the largest share, 36.5%, and was dominated by tablets/capsules, which are more convenient, cost-effective, and prescribed broadly in both hormonal as well as non-hormonal categories. Patches proliferate because of improved patient adherence, little to no hepatic metabolism, and established long-term robust clinical data on hormone therapy.
By Indication
The menopause stage was the dominant segment in 2024, with a market share of 49.3% as most treatment decisions and interventions are made after cessation of menstruation. Prevalence of perimenopause is expanding most rapidly because of increased earlier diagnosis and increasing awareness, as well as the direction to early symptom control to avert organized sequelae.
By Distribution Channel
Retail Pharmacies dominated by 43.1% share in 2024, based on large geographic access, easier treatment of hormonal drugs, and greater demand for over-the-counter supplements. Online Pharmacies, a direct-to-consumer platform, in the COVID-19 era, where Telehealth is picking up immensely with increasing e-commerce penetration, online pharmacies are scaling rapidly.
Regional Analysis:
North America held a 36.1% share of the market based on revenue in 2024, due to high healthcare spending, widespread availability of hormone replacement therapies (HRT), and developed reimbursed systems.
The U.S. menopause treatment market size was valued at USD 5.36 billion in 2024 and is expected to reach USD 7.72 billion by 2032, growing at a CAGR of 4.63% over 2025-2032. The North American contribution of the U.S. to more than 75% was born on reasonable awareness among physicians and well-developed R&D pipelines, especially in the U.S., led by Pfizer, followed by Organon and Amneal. As well, an increasing adoption of digital health platforms and the rise of OTC supplement utilization could have benefits for the nation. Canada is incrementally growing on the back of government initiatives, which are focusing on women's health and enhanced access to therapies via provincial drug plans. It is also experiencing a rise in clinical trial activity, and the FDA is granting regulatory approvals in a faster time, both of which help catalyze innovation.
Rising awareness of menopausal issues is also boosting the market in the Asia Pacific, which will see significant growth as countries such as China and India build better healthcare infrastructure. Rising rates of diagnosis and urbanization, coupled with a robust uptake of therapies, are expected to uplift the growth prospects in the region. The market is led by Japan due to a very large postmenopausal population (over 32 million) and extensive insurance coverage. Growing healthcare spending in China and the growing presence of both domestic players and global pharma companies looking to expand access to HRT are also helping to transform that market. In India, due to increasing technological advancements and the growing number of gynecological issues, over-the-counter drugs as well as natural remedies are experiencing double-digit growth. Moreover, countries such as South Korea and Australia are experiencing a demand explosion due to an increase in wellness trends and proactive midlife health management.
Key Players:
Leading menopause treatment companies include Theramex, Pure Encapsulations LLC, Dr. Reddy’s Laboratories Ltd., ReNew Life Holdings Corporation, Padagis, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Mithra Pharmaceuticals, Merck & Co. Inc., Cipla Inc., Abbott, Viatris Inc., Organon, SnapNurse, Glenmark Pharmaceuticals Ltd., Procter & Gamble, Duchesnay USA, TherapeuticsMD Inc., Avion Pharmaceuticals, and PharmaCare Europe Ltd.
Recent Developments:
In July 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved elinzanetant (Lynkuet), an oral dual NK‑1/NK‑3 receptor antagonist, as a first-in-class non-hormonal therapy for moderate to severe hot flashes associated with menopause. This marks the global debut authorization for a novel non-hormonal menopause treatment.
In October 2024, the U.S. FDA accepted Bayer’s New Drug Application (NDA) for elinzanetant, backed by positive outcomes from three Phase III OASIS studies. The PDUFA review date is set for July 2025, positioning it as a potential new option in non-hormonal menopause management.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 17.84 billion |
| Market Size by 2032 | USD 27.23 billion |
| CAGR | CAGR of 5.44% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment Type [Hormonal Therapies (Estrogen-based, Progestin-based, Combination), Non-Hormonal Therapies (Neurokinin-3 (NK3) Receptor Antagonists, Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Gabapentinoids, Phytoestrogens & Herbal Products), and Others (Cognitive Behavioral Therapy (CBT), Lifestyle & Dietary Supplements)] • By Route of Administration [Oral, Topical/Transdermal, Vaginal, and Parenteral] • By Formulation Type [Tablets/Capsules, Creams/Gels, Patches, Vaginal Rings & Pessaries, Injections, and Others] • By Indication [Perimenopause, Menopause, Postmenopause], Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Clinics & Stores] |
| Regional Analysis/Coverage | North America (U.S., Canada), Europe (Germany, France, UK, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, Egypt, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America) |
| Company Profiles | Theramex, Pure Encapsulations LLC, Dr. Reddy’s Laboratories Ltd., ReNew Life Holdings Corporation, Padagis, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Mithra Pharmaceuticals, Merck & Co. Inc., Cipla Inc., Abbott, Viatris Inc., Organon, SnapNurse, Glenmark Pharmaceuticals Ltd., Procter & Gamble, Duchesnay USA, TherapeuticsMD Inc., Avion Pharmaceuticals, and PharmaCare Europe Ltd. |
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Treatment Type
2.3.2 Market Size By Route of Administration
2.3.3 Market Size By Formulation Type
2.3.4 Market Size By Indication
2.3.5 Market Size By Distribution Channel
2.4 Market Share & BPS Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Life Cycle Assessment
3.5 Parent Market Overview
3.6 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Reimbursement & Coverage Trends
4.1.1 Country-wise Payer Coverage Analysis
4.1.2 Cost-Effectiveness and HTA Trends
4.2 R&D Investment and Funding Trends
4.2.1 Venture Capital and IPO Activity (2020–2024)
4.2.2 Public-Private and Regulatory-Backed Initiatives
4.3 Technology Integration Trends
4.3.1 AI and Predictive Analytics in Personalized Menopause Care
4.3.2 Digital Health Platforms and DTC Solutions
4.4 Clinical Trials and Pipeline Progression Metrics
4.4.1 Menopause Drug Pipeline by Therapy Class
4.4.2 Trial Enrollment and Accessibility Insights
4.5 Market Penetration and Adoption Metrics
4.5.1 HRT and Non-HRT Treatment Adoption Rates
4.5.2 New Patient Initiation and Adherence Rates
5. Menopause Treatment Market Segmental Analysis & Forecast, By Treatment Type, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Hormonal Therapies
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.2.3 Estrogen-based Therapies
5.2.3.1 Key Trends
5.2.3.2 Market Size & Forecast, 2021 – 2032
5.2.3 Progestin-based Therapies
5.2.3.1 Key Trends
5.2.3.2 Market Size & Forecast, 2021 – 2032
5.2.3 Combination Therapies
5.2.3.1 Key Trends
5.2.3.2 Market Size & Forecast, 2021 – 2032
5.2 Non-Hormonal Therapies
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.2.3 Neurokinin-3 (NK3) Receptor Antagonists
5.2.3.1 Key Trends
5.2.3.2 Market Size & Forecast, 2021 – 2032
5.2.4 Selective Serotonin Reuptake Inhibitors (SSRIs)
5.2.4.1 Key Trends
5.2.4.2 Market Size & Forecast, 2021 – 2032
5.2.5 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
5.2.5.1 Key Trends
5.2.5.2 Market Size & Forecast, 2021 – 2032
5.2.6 Gabapentinoids
5.2.6.1 Key Trends
5.2.6.2 Market Size & Forecast, 2021 – 2032
5.2.7 Phytoestrogens & Herbal Products
5.2.7.1 Key Trends
5.2.7.2 Market Size & Forecast, 2021 – 2032
5.3 Others (Cognitive Behavioral Therapy (CBT), Lifestyle & Dietary Supplements)
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
6. Menopause Treatment Market Segmental Analysis & Forecast, By Route of Administration, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Oral
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Topical/Transdermal
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Vaginal
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
6.5 Parenteral
6.5.1 Key Trends
6.5.2 Market Size & Forecast, 2021 – 2032
7. Menopause Treatment Market Segmental Analysis & Forecast, By Formulation Type, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Tablets/Capsules
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Creams/Gels
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 Patches
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
7.5 Vaginal Rings & Pessaries
7.5.1 Key Trends
7.5.2 Market Size & Forecast, 2021 – 2032
7.6 Injections
7.6.1 Key Trends
7.6.2 Market Size & Forecast, 2021 – 2032
7.7 Others (Oral Dissolving Films, and Extended-release Pellets)
7.7.1 Key Trends
7.7.2 Market Size & Forecast, 2021 – 2032
8. Menopause Treatment Market Segmental Analysis & Forecast, By Indication, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Perimenopause
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Menopause
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Postmenopause
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
9. Menopause Treatment Market Segmental Analysis & Forecast, By Distribution Channel, 2021 – 2032, Value (USD Billion)
9.1 Introduction
9.2 Hospital Pharmacies
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2021 – 2032
9.3 Retail Pharmacies
9.3.1 Key Trends
9.3.2 Market Size & Forecast, 2021 – 2032
9.4 Online Pharmacies
9.4.1 Key Trends
9.4.2 Market Size & Forecast, 2021 – 2032
9.5 Specialty Clinics & Stores
9.5.1 Key Trends
9.5.2 Market Size & Forecast, 2021 – 2032
10. Menopause Treatment Market Segmental Analysis & Forecast By Region, 2021 – 2032, Value (USD Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.2.3 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.2.4 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.2.5 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.2.6 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.2.7 Menopause Treatment Market Size & Forecast, By Country, 2021 – 2032
10.2.7.1 USA
10.2.7.1.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.2.7.1.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.2.7.1.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.2.7.1.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.2.7.1.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.2.7.2 Canada
10.2.7.2.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.2.7.2.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.2.7.2.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.2.7.2.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.2.7.2.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3 Europe
10.3.1 Key Trends
10.3.2 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.3 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.4 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.5 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.6 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7 Menopause Treatment Market Size & Forecast, By Country, 2021 – 2032
10.3.7.1 Germany
10.3.7.1.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.1.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.1.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.1.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.1.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.2 UK
10.3.7.2.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.2.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.2.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.2.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.2.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.3 France
10.3.7.3.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.3.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.3.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.3.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.3.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.4 Italy
10.3.7.4.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.4.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.4.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.4.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.4.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.5 Spain
10.3.7.5.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.5.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.5.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.5.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.5.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.6 Russia
10.3.7.6.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.6.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.6.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.6.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.6.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.7 Poland
10.3.7.7.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.7.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.7.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.7.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.7.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.3.7.8 Rest of Europe
10.3.7.8.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.3.7.8.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.3.7.8.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.3.7.8.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.3.7.8.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.3 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.4 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.5 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.6 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7 Menopause Treatment Market Size & Forecast, By Country, 2021 – 2032
10.4.7.1 China
10.4.7.1.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.1.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.1.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.7.1.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.7.1.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.2 India
10.4.7.2.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.2.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.2.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.7.2.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.7.2.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.3 Japan
10.4.7.3.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.3.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.3.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.7.3.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.7.3.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.4 South Korea
10.4.7.4.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.4.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.4.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.7.4.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.7.4.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.5 Australia
10.4.7.5.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.5.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.5.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.7.5.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.7.5.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.6 ASEAN Countries
10.4.7.6.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.6.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.6.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.7.6.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.7.6.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.4.7.7 Rest of Asia-Pacific
10.4.7.7.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.4.7.7.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.4.7.7.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.4.7.7.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.4.7.7.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5 Latin America
10.5.1 Key Trends
10.5.2 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.3 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.4 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.5.5 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.5.6 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7 Menopause Treatment Market Size & Forecast, By Country, 2021 – 2032
10.5.7.1 Brazil
10.5.7.1.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.1.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.1.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.5.7.1.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.5.7.1.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.2 Argentina
10.5.7.2.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.2.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.2.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.5.7.2.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.5.7.2.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.3 Mexico
10.5.7.3.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.3.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.3.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.5.7.3.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.5.7.3.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.4 Colombia
10.5.7.4.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.4.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.4.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.5.7.4.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.5.7.4.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.5.7.5 Rest of Latin America
10.5.7.5.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.5.7.5.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.5.7.5.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.5.7.5.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.5.7.5.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.3 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.4 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.6.5 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.6.6 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7 Menopause Treatment Market Size & Forecast, By Country, 2021 – 2032
10.6.7.1 UAE
10.6.7.1.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.1.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.1.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.6.7.1.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.6.7.1.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.2 Saudi Arabia
10.6.7.2.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.2.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.2.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.6.7.2.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.6.7.2.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.3 Qatar
10.6.7.3.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.3.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.3.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.6.7.3.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.6.7.3.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.4 Egypt
10.6.7.4.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.4.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.4.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.6.7.4.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.6.7.4.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.5 South Africa
10.6.7.5.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.5.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.5.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.6.7.5.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.6.7.5.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
10.6.7.6 Rest of Middle East & Africa
10.6.7.6.1 Menopause Treatment Market Size & Forecast, By Treatment Type, 2021 – 2032
10.6.7.6.2 Menopause Treatment Market Size & Forecast, By Route of Administration, 2021 – 2032
10.6.7.6.3 Menopause Treatment Market Size & Forecast, By Formulation Type, 2021 – 2032
10.6.7.6.4 Menopause Treatment Market Size & Forecast, By Indication, 2021 – 2032
10.6.7.6.5 Menopause Treatment Market Size & Forecast, By Distribution Channel, 2021 – 2032
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2024
11.2.2 Year-Wise Strategies & Development, 2021 – 2025
11.2.3 Number of Strategies Adopted by Key Players, 2024
11.3 Market Share Analysis, 2024
11.4 Product/Service & Sensor Size Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Sensor Size Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6 Key Company Profiles
11.6.1 Theramex
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 Pure Encapsulations LLC
11.6.2.1 Company Overview & Snapshot
11.6.2.2 Product/Service Portfolio
11.6.2.3 Key Company Financials
11.6.2.4 SWOT Analysis
11.6.3 Dr. Reddy’s Laboratories Ltd.
11.6.3.1 Company Overview & Snapshot
11.6.3.2 Product/Service Portfolio
11.6.3.3 Key Company Financials
11.6.3.4 SWOT Analysis
11.6.4 ReNew Life Holdings Corporation
11.6.4.1 Company Overview & Snapshot
11.6.4.2 Product/Service Portfolio
11.6.4.3 Key Company Financials
11.6.4.4 SWOT Analysis
11.6.5 Padagis
11.6.5.1 Company Overview & Snapshot
11.6.5.2 Product/Service Portfolio
11.6.5.3 Key Company Financials
11.6.5.4 SWOT Analysis
11.6.6 Teva Pharmaceutical Industries Ltd.
11.6.6.1 Company Overview & Snapshot
11.6.6.2 Product/Service Portfolio
11.6.6.3 Key Company Financials
11.6.6.4 SWOT Analysis
11.6.7 Novo Nordisk A/S
11.6.7.1 Company Overview & Snapshot
11.6.7.2 Product/Service Portfolio
11.6.7.3 Key Company Financials
11.6.7.4 SWOT Analysis
11.6.8 Mithra Pharmaceuticals
11.6.8.1 Company Overview & Snapshot
11.6.8.2 Product/Service Portfolio
11.6.8.3 Key Company Financials
11.6.8.4 SWOT Analysis
11.6.9 Merck & Co. Inc.
11.6.9.1 Company Overview & Snapshot
11.6.9.2 Product/Service Portfolio
11.6.9.3 Key Company Financials
11.6.9.4 SWOT Analysis
11.6.10 Cipla Inc.
11.6.10.1 Company Overview & Snapshot
11.6.10.2 Product/Service Portfolio
11.6.10.3 Key Company Financials
11.6.10.4 SWOT Analysis
11.6.11 Abbott
11.6.11.1 Company Overview & Snapshot
11.6.11.2 Product/Service Portfolio
11.6.11.3 Key Company Financials
11.6.11.4 SWOT Analysis
11.6.12 Viatris Inc.
11.6.12.1 Company Overview & Snapshot
11.6.12.2 Product/Service Portfolio
11.6.12.3 Key Company Financials
11.6.12.4 SWOT Analysis
11.6.13 Organon
11.6.13.1 Company Overview & Snapshot
11.6.13.2 Product/Service Portfolio
11.6.13.3 Key Company Financials
11.6.13.4 SWOT Analysis
11.6.14 SnapNurse
11.6.14.1 Company Overview & Snapshot
11.6.14.2 Product/Service Portfolio
11.6.14.3 Key Company Financials
11.6.14.4 SWOT Analysis
11.6.15 Glenmark Pharmaceuticals Ltd.
11.6.15.1 Company Overview & Snapshot
11.6.15.2 Product/Service Portfolio
11.6.15.3 Key Company Financials
11.6.15.4 SWOT Analysis
11.6.16 Procter & Gamble
11.6.16.1 Company Overview & Snapshot
11.6.16.2 Product/Service Portfolio
11.6.16.3 Key Company Financials
11.6.16.4 SWOT Analysis
11.6.17 Duchesnay USA
11.6.17.1 Company Overview & Snapshot
11.6.17.2 Product/Service Portfolio
11.6.17.3 Key Company Financials
11.6.17.4 SWOT Analysis
11.6.18 TherapeuticsMD Inc.
11.6.18.1 Company Overview & Snapshot
11.6.18.2 Product/Service Portfolio
11.6.18.3 Key Company Financials
11.6.18.4 SWOT Analysis
11.6.19 Avion Pharmaceuticals
11.6.19.1 Company Overview & Snapshot
11.6.19.2 Product/Service Portfolio
11.6.19.3 Key Company Financials
11.6.19.4 SWOT Analysis
11.6.20 PharmaCare Europe Ltd
11.6.20.1 Company Overview & Snapshot
11.6.20.2 Product/Service Portfolio
11.6.20.3 Key Company Financials
11.6.20.4 SWOT Analysis
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions On Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List Of Tables
15.2 List Of Figures
Key Segments
By Treatment Type
- Hormonal Therapies
- Estrogen-based Therapies
- Progestin-based Therapies
- Combination Therapies
- Non-Hormonal Therapies
- Neurokinin-3 (NK3) Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Gabapentinoids
- Phytoestrogens & Herbal Products
- Others (Cognitive Behavioral Therapy (CBT), Lifestyle & Dietary Supplements)
By Route of Administration
- Oral
- Topical/Transdermal
- Vaginal
- Parenteral
By Formulation Type
- Tablets/Capsules
- Creams/Gels
- Patches
- Vaginal Rings & Pessaries
- Injections
- Others (Oral Dissolving Films, and Extended-release Pellets)
By Indication
- Perimenopause
- Menopause
- Postmenopause
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics & Stores
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
